PI-103

PI-103は一種の多ターゲットPI3K抑制剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は2 nM/3 nM/3 nM/15 nMです。PI-103はmTOR/DNA-PKに作用する効果が弱くて、このIC50値が30 nM/23 nMになります。

価格 在庫  
USD 168 あり
USD 185 あり
USD 340 あり
USD 466 あり

PI-103 化学構造
分子量: 348.36

高品質保証

カスタマーフィードバック(4)

MSDS

製品説明

  • Compare PI3K Inhibitors
    PI3K製品生物活性の比較
  • 研究分野
  • PI-103のメカニズム

製品の説明

生物活性

製品説明 PI-103は一種の多ターゲットPI3K抑制剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は2 nM/3 nM/3 nM/15 nMです。PI-103はmTOR/DNA-PKに作用する効果が弱くて、このIC50値が30 nM/23 nMになります。
ターゲット p110α p110β p110δ p110γ mTOR DNA-PK
IC50 2 nM 3 nM 3 nM 15 nM 30 nM 23 nM [3]
In vitro試験 PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SK-N-BE NUfiN4dTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[1NE05KM7:TR?= M37NflI1NzR6L{eyJIg> M2WwUIlv\HWlZYOgeIlu\S1iYX7kJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnubIljcXSrb36gc44hVkJiY3XscEBoem:5dHi= NIXHT2UzPjJ{NE[4NS=>
SH-SY5Y M1;1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPLfpQxNThizszN M4\KVVI1NzR6L{eyJIg> NHztcVZqdmS3Y3XzJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcohq[mm2aX;uJI9vKE6EIHPlcIwh\3Kxd4To M1z3NlI3OjJ2Nkix
SH-SY5Y  NXHEdXNFSXCxcITvd4l{KEG|c3H5 NWLnRVY6OSEQvF2= NWToW2ZpOC53LUK0JIg> MmS2d4Vve2m2aYrld{Bv\XW{b3LsZZN1d22jIHPlcIx{KHSxIHTvfI9zfWKrY3nuMYlv\HWlZXSgZZBweHSxc3nz MX6yOlIzPDZ6MR?=
G 35 SC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofqNE4xPS1{MDFOwG0> M{HmR|I1Nzd{IHi= M1XvU2ROW09? M1LUcYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? MknqNlYyOjF{NUG=
G 38 SC NWTNWmdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XaNFAvODVvMkCg{txO MlXBNlQwPzJiaB?= MoqxSG1UVw>? MlTBbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? MknaNlYyOjF{NUG=
G 40 SC NETiUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWwMlA2NTJyIN88US=> M{fSdFI1Nzd{IHi= M3HYT2ROW09? MY\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M33udFI3OTJzMkWx
G 35 DC M{PjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW2[HFDOC5yNT2yNEDPxE1? M1ThSlI1Nzd{IHi= NUDDVnpwTE2VTx?= M1zGN4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? M3XtbVI3OTJzMkWx
G 38 DC MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnLZ2o6OC5yNT2yNEDPxE1? M3nPblI1Nzd{IHi= NVr5Um4yTE2VTx?= Mn\ObY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? MkjhNlYyOjF{NUG=
G 40 DC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjxZYY{OC5yNT2yNEDPxE1? MlXMNlQwPzJiaB?= NHfZRYpFVVOR MWfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 MmfINlYyOjF{NUG=
RD M3LQ[WFxd3C2b4Ppd{BCe3OjeR?= MmqxNU8yNjVxMjFOwG0> NGT5fY44OiCq MlHqbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> M2H1V|I2PzR7M{e4
TE381.T NWLyToh2SXCxcITvd4l{KEG|c3H5 NF;kNHoyNzFwNT:yJO69VQ>? NH;Bbo04OiCq NWTv[nBpcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? M4XZVFI2PzR7M{e4
RMS13 MmH0RZBweHSxc3nzJGF{e2G7 MojLNU8yNjVxMjFOwG0> MmjPO|IhcA>? MmTabY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> NWPUTopXOjV5NEmzO|g>
RH30  Ml:3RZBweHSxc3nzJGF{e2G7 MnTtNU8yNjVxMjFOwG0> Mn3xO|IhcA>? MV3pcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> NIm4WpEzPTd2OUO3PC=>
VJ M{jXR2Fxd3C2b4Ppd{BCe3OjeR?= MmjLNU8yNjVxMjFOwG0> MkfNO|IhcA>? MXTpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> MYiyOVc1QTN5OB?=
HS578T M1zmemNmdGxiVnnhZoltcXS7IFHzd4F6 MkDkNE0{KM7:TR?= NULNRZpkPzJiaB?= NVjHcGlDcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NVzDVmlKOjV5MkG0NVk>
BT549 M1KzTmNmdGxiVnnhZoltcXS7IFHzd4F6 NHLLemgxNTNizszN NULKV5ppPzJiaB?= M1jPVYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NXPNNVhLOjV5MkG0NVk>
MDA-MB-231 MWDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWfjdHFbOC1|IN88US=> NGmxdFQ4OiCq M1jESIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? Mke4NlU4OjF2MUm=
MDA-MB-468 NVTVbIk3S2WubDDWbYFjcWyrdImgRZN{[Xl? MXWwMVMh|ryP M4fMR|czKGh? NVLyVW1JcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MWKyOVczOTRzOR?=
MDA-MB-436 NHPvUZdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MY[wMVMh|ryP MlTMO|IhcA>? NWPpSpJRcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M2PJNlI2PzJzNEG5
SUM149PT Mm\iR4VtdCCYaXHibYxqfHliQYPzZZk> NVPaXHQzOC1|IN88US=> NUTpXmxVPzJiaB?= NHXmemNqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NYPBVoY4OjV5MkG0NVk>
MDA-MB-468 NGfKTppHfW6ldHnvckBCe3OjeR?= NH;RNZIxNjBzLUGwJO69VQ>? M4fnT|I1KGh? NYfwd|Q{\G:5boLl[5Vt[XSnczD0bIUhdGW4ZXzzJI9nKM7{LWTyR3AyNCClLV35Z{BidmRiY4njcIlvKEVicILveIVqdnQEoB?= NUn6doFqOjV5MkG0NVk>
MDA-MB-231 M{jrfGZ2dmO2aX;uJGF{e2G7 MVGwMlAyNTFyIN88US=> NILMW5UzPCCq MX3kc5dvemWpdXzheIV{KHSqZTDs[ZZmdHNib3[g{tIuXHKFUEGsJIMuVXmlIHHu[EBkgWOuaX6gSUBxem:2ZXnud:Kh NWDNZ3hxOjV5MkG0NVk>
HS578T NIHWPJRHfW6ldHnvckBCe3OjeR?= NHr6c5oxNjBzLUGwJO69VQ>? NVHmVJhtOjRiaB?= MYTkc5dvemWpdXzheIV{KHSqZTDs[ZZmdHNib3[g{tIuXHKFUEGsJIMuVXmlIHHu[EBkgWOuaX6gSUBxem:2ZXnud:Kh M3nMZlI2PzJzNEG5
SW872 M2e2dWZ2dmO2aX;uJGF{e2G7 M2foNlAvODFvMD61JO69VQ>? MmDWNlQhcA>? NWDGW5JOemWmdXPld{BCU1RicHjvd5Bpd3K7bHH0bY9vKCiyQVvULUBidmRiNFXCVFEheGixc4Doc5J6dGG2aX;uJEhxPEWEUEGpJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NULDXYRiOjR4OUW2N|I>
SW982 M3Hzd2Z2dmO2aX;uJGF{e2G7 MWWwMlAyNTBwNTFOwG0> M134c|I1KGh? MUTy[YR2[2W|IFHLWEBxcG:|cHjvdplt[XSrb36gLJBCU1RrIHHu[EA1TUKSMTDwbI9{eGixconsZZRqd25iKIC0SWJROSliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= NEHhZYszPDZ7NU[zNi=>
SW872 MXHBdI9xfG:|aYOgRZN{[Xl? Mmi1NE4xOS1yLkWg{txO M1PQbVQ5KGh? Moj6bY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MYKyOFY6PTZ|Mh?=
SW982 MkXPRZBweHSxc3nzJGF{e2G7 NXPDXm54OC5yMT2wMlUh|ryP NGf6dmY1QCCq NVrQcGt6cW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NXzzXlZQOjR4OUW2N|I>
AGS HG MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwNkigxtEhOC5yM{Gg{txO MUmyOFU6PzR5OB?=
AGS LG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzm[nRKSzVyPUCuNFUhyrFiMD6wNFEh|ryP M4LUPFI1PTl5NEe4
HGC27 HG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXiWHhKSzVyPUCuN|ghyrFiMD6wNlIh|ryP NXzPVI5sOjR3OUe0O|g>
HGC27 LG Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;lemlEPTB;MD6wNkDDuSByLkCwOEDPxE1? MYqyOFU6PzR5OB?=
MKN45 HG NX\2cHp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLHTWM2OD1zLkCxJOKyKDBwMEWxJO69VQ>? NWnkOXZpOjR3OUe0O|g>
MKN45 LG MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrScmxwUUN3ME2wMlg4KMLzIECuNFMxKM7:TR?= NIjOW4szPDV7N{S3PC=>
NUGC4 HG M4PD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjsTWM2OD1zND6wJOKyKDNwOUGzJO69VQ>? NWTSNmtyOjR3OUe0O|g>
NUGC4 LG MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF2LkCgxtEhPS5|MkGg{txO MojzNlQ2QTd2N{i=
A549 NHrIR3hHfW6ldHnvckBCe3OjeR?= MY[wMlI2NzBwNT:xJO69VQ>? Mm\FNlQhcA>? NVLFeFhMcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|bHnnbJRtgQ>? MYqyOFM2OTR{NR?=
H460 NVjkeFliTnWwY4Tpc44hSXO|YYm= M2PkN|AvOjVxMD61M|Eh|ryP Mk\6NlQhcA>? NY\CR|FMcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|bHnnbJRtgQ>? M2KyWFI1OzVzNEK1
H661 MVnGeY5kfGmxbjDBd5NigQ>? M2fUNVAvOjVxMD61M|Eh|ryP NXWxb2JWOjRiaB?= MU\pcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? NIO1VnIzPDN3MUSyOS=>
SAS M2rRRWZ2dmO2aX;uJGF{e2G7 MWSwMlI2NzBwNT:xJO69VQ>? MnHUNlQhcA>? Mnn3bY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{cWewaX\pZ4FvfGy7 M3rFW|I1OzVzNEK1
UT5 NEfWdlhHfW6ldHnvckBCe3OjeR?= MnLtNE4zPS9yLkWvNUDPxE1? MnTKNlQhcA>? MWXpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? NFWyNmczPDN3MUSyOS=>
FaDu NUexWmNqTnWwY4Tpc44hSXO|YYm= NUGyWZY5OC5{NT:wMlUwOSEQvF2= M3rhWFI1KGh? MYTpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? NITMW2szPDN3MUSyOS=>
RD M3\2UGFxd3C2b4Ppd{BCe3OjeR?= MVuxM|EvPS9{IN88US=> NHnXeHo4OiCq NVXaXlRyTE2VTx?= NWrXTWxzcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDVU|EzPg>? MYWyN|Y5PDl{NR?=
TE671 M2DPdWFxd3C2b4Ppd{BCe3OjeR?= MX2xM|EvPS9{IN88US=> NVjyOZRxPzJiaB?= MWjEUXNQ MX\pcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKFWRMUK2 MV[yN|Y5PDl{NR?=
RH30  NGjOV4dCeG:ydH;zbZMhSXO|YYm= M{PYOVEwOS53L{Kg{txO MVi3NkBp M3;pPGROW09? M2PIVYlv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiVV:xNlY> Mn\TNlM3QDR7MkW=
RMS13 NUnWcFI5SXCxcITvd4l{KEG|c3H5 MW[xM|EvPS9{IN88US=> M2HYeFczKGh? MmPaSG1UVw>? NH3WZXNqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 NXzn[W1ROjN4OES5NlU>
SUM149PT NU\PXW5QS2WubDDWbYFjcWyrdImgRZN{[Xl? NVjoe5dIOC5|IN88US=> Mm\3O|IhcA>? MUjlcohidmOnczDjfZRwfG:6aXOg[YZn\WO2czDv[kBRUTONL1HLWEBx[XSqd3H5JIlvcGmkaYTvdpM> NVi4RWZZOjN4MEGwO|Q>
MDA-MB-468 MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIW0fFYxNjNizszN MWK3NkBp NEjSSWRmdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN? M2\DdFI{PjBzMEe0
MDA-MB-231 M3W1bWNmdGxiVnnhZoltcXS7IFHzd4F6 M{SxR|AvOyEQvF2= MnfiO|IhcA>? NXnMZYNL\W6qYX7j[ZMh[3m2b4TvfIlkKGWoZnXjeJMhd2ZiUFmzT{9CU1RicHH0bJdigSCrbnjpZol1d3K| MlLGNlM3ODFyN{S=
SY5Y MWLGeY5kfGmxbjDBd5NigQ>? MojHNU42NzJwNT:1JO69VQ>? MmXCNlQhcA>? NHrrfpBqdmS3Y3XzJGcyyqClZXzsMYN6[2ynIHHydoV{fCCjbnSgZZBweHSxc3nz NFLQfJAzOzN5OEO0NS=>
SKNBE(2c) MX7GeY5kfGmxbjDBd5NigQ>? NF;0WnAyNjVxMj61M|Uh|ryP NVHGNVZIOjRiaB?= MY\pcoR2[2W|IFexxsBk\WyuLXP5Z4xmKGG{cnXzeEBidmRiYYDvdJRwe2m| MXuyN|M4QDN2MR?=
RD NHmxTI1CeG:ydH;zbZMhSXO|YYm= MXizJOK2VQ>? NEDQ[FIyOiCq NUmy[IZTTE2VTx?= NVjrZlNWe2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM> MlzkNlM{ODB6MEm=
TP5014 NEH5bWxCeG:ydH;zbZMhSXO|YYm= NIXMenk{KML3TR?= MVWxNkBp M1nHWGROW09? MoPyd4Vve2m2aYrld{BTTCClZXzsd{B1dyCGT2itbY5lfWOnZDDhdI9xfG:|aYO= MVqyN|MxODhyOR?=
HT1080 MlvYRZBweHSxc3nzJGF{e2G7 MYqzJOK2VQ>? NWTUdGxbOTJiaB?= M1rwU2ROW09? M{HsU5NmdnOrdHn6[ZMhWkRiY3XscJMhfG9iRF;YMYlv\HWlZXSgZZBweHSxc3nz NEjJNJIzOzNyMEiwPS=>
A549 MV\GeY5kfGmxbjDBd5NigQ>? M3TBcFAuOy5|IN88US=> MVK3NkBp MVTpcoR2[2W|IHPvcZBt\XSnIHTve45z\We3bHH0bY9vKG:oIIDBT3Q> NXzIPGpLOjN{NUm1PVE>
HCC827 NUHI[JdzTnWwY4Tpc44hSXO|YYm= MkfSNE0{NjNizszN NYfFe2N5PzJiaB?= NH3xNlJqdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? MmPHNlMzPTl3OUG=
H3122 NGOxWJRHfW6ldHnvckBCe3OjeR?= MkTGNE0{NjNizszN MoDHO|IhcA>? NGTJ[I5qdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? MVqyN|I2QTV7MR?=
TALL-1 NF[0OXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO2NgKBkc7:TR?= NXSwWo03PyCm MoXT[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NYjyXoRSOjNyM{iyO|M>
HPB-ALL NXywSXdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vpXVHjiIoQvF2= MnzzO{Bl MW\k[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MmHnNlMxOzh{N{O=
DND41 M{O3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV2x5qCK|ryP NYjhdodjPyCm MXXk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> Mme4NlMxOzh{N{O=
SUP-T1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\VNgKBkc7:TR?= NUHWfZV2PyCm M{\ROIRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NEDUXpYzOzB|OEK3Ny=>
PEER M{\SdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXBNgKBkc7:TR?= M3rLTVch\A>? MV;k[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> M{G3dlI{ODN6Mkez
ALL-SIL M3u0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfTOoFMOeLCid88US=> Mk\mO{Bl Ml:1[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 M3;XSlI{ODN6Mkez
KE37 NFvQPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPKNgKBkc7:TR?= MYS3JIQ> M335fYRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MWOyN|A{QDJ5Mx?=
Karpas-45 NFvoNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6x5qCK|ryP MkjYO{Bl NVfWbWlo\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MWCyN|A{QDJ5Mx?=
RPMI-8402 NVSzUWZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:5NgKBkc7:TR?= M{HZTVch\A>? M4P0ZoRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MXiyN|A{QDJ5Mx?=
Jurkat MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrGNgKBkc7:TR?= M2DrWVch\A>? MXLk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NVfJSYVPOjNyM{iyO|M>
MOLT-4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\QZ|HjiIoQvF2= NVP5W4J6PyCm NH;2fItl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NIDSc48zOzB|OEK3Ny=>
PF-382 NF\Db2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTJOWNNOeLCid88US=> MX:3JIQ> M1XqOoRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NYq0RWp1OjNyM{iyO|M>
CCRF-CEM M2rWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnNSWkyOeLCid88US=> M321XFch\A>? NVHK[Yw{\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 M{fZUFI{ODN6Mkez
LOUCY M2[4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDINgKBkc7:TR?= Mm[1O{Bl NVPabFB[\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 NXvOOpRFOjNyM{iyO|M>
MOLT-16 Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqx5qCK|ryP NYPFbYRyPyCm M2fkToRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MV:yN|A{QDJ5Mx?=
MM1S MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fES|AuOiEQvF2= NIOzeG4zPCCq NX23NphOUUN3ME2wMlUh|ryP NGr1R40zOjh{OUKzOC=>
NCI-H929 NFLGNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH3ZVExNTJizszN M37xfFI1KGh? NHPSO4ZKSzVyPUCuNlUh|ryP M{nTS|IzQDJ7MkO0
KMS12-BM  Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2mzZVAuOiEQvF2= MkHRNlQhcA>? NFzLOJpKSzVy78{eNkDPxE1? NEjzc3ozOjh{OUKzOC=>
MDA-MB-436 M3rPPWZ2dmO2aX;uJGF{e2G7 NI[3UXoyKM7:TR?= MUmyOEBp NH3BcVVz\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvU NYfoTpRTOjJ2OEi1PVA>
SUM149PT NGLIZ|BHfW6ldHnvckBCe3OjeR?= M4PC[VEh|ryP NFW2O4QzPCCq M3;QdZJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2S= M13WZ|IzPDh6NUmw
SUM1315MO2 MYfGeY5kfGmxbjDBd5NigQ>? NXLRbGptOSEQvF2= NFj5W2ozPCCq NXHKS286emWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> M4jFR|IzPDh6NUmw
HCC1937 NFHmeHdHfW6ldHnvckBCe3OjeR?= NU\5e|FOOSEQvF2= NFfBNpozPCCq MX;y[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW MkDvNlI1QDh3OUC=
HCC827 MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDXZlAxNTNizszN NYnhfIo{PzJiaB?= MUfJR|UxRTBwMzFOwG0> NUH5eFVnOjF{MkC0O|Q>
PC-9  NILmNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjaNE0{KM7:TR?= M2C5cVczKGh? MmL3TWM2OD1yLkig{txO NXfHPY1xOjF{MkC0O|Q>
LN229 MoDHSpVv[3Srb36gRZN{[Xl? NWDHW2J7OSEQvF2= Mn:1OFghcA>? NFXHXo9qdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:w NGPVXY4zOTB4Mkm5Ny=>
U87 NWThXlJzTnWwY4Tpc44hSXO|YYm= M2LQc|Eh|ryP M4HJO|Q5KGh? MoTybY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? NUixUWVlOjFyNkK5PVM>
U373 M3WwcWZ2dmO2aX;uJGF{e2G7 MVOxJO69VQ>? NWPuR|hjPDhiaB?= NF7pZWpqdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:w NV7jW3Q{OjFyNkK5PVM>
SF767 MXvGeY5kfGmxbjDBd5NigQ>? M3XlUVEh|ryP MmXHOFghcA>? NYrkU5JLcW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= MnT5NlExPjJ7OUO=
Mel-Juso MkTWR4VtdCCYaXHibYxqfHliQYPzZZk> MUiwMlAy6oDVMUFihKnPxE1? MWe3NkBp NI\nVWtqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MXKyNVA1QDd6NR?=
518A2  Mo\HR4VtdCCYaXHibYxqfHliQYPzZZk> MofMNE4xOeLCk{Gw5qCK|ryP NIO5WlU4OiCq MnHObY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MWKyNVA1QDd6NR?=
Mel-Juso  MXHGeY5kfGmxbjDBd5NigQ>? M{[2cFAvODBz4pETNgKBkc7:TR?= M2rDOlI1KGh? MX7zeZBxemW|c3XzJJBpd3OyaH;yfYxifGmxbjDv[kBxcG:|cHjheIllgWxiaX7vd4l1d2xiMz3rbY5ie2ViZH;3cpN1emWjbTD0ZZJo\XS| NIrUdlUzOTB2OEe4OS=>
518A2 NW[2flBHTnWwY4Tpc44hSXO|YYm= MXOwMlAxOeLCk{JihKnPxE1? MnTENlQhcA>? MoHDd5VxeHKnc4Pld{BxcG:|cHjvdplt[XSrb36gc4YheGixc4DoZZRq\HmuIHnuc5NqfG:uIEOtb4lv[XOnIHTve45{fHKnYX2geIFz\2W2cx?= NWHMfGp6OjFyNEi3PFU>
PC3  NH7BUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DiV|I1cA>? NUXvcINDT0l3MNMgQUAyODBibl2= M2LmeVIxPTVzME[x
U87MG MmnlSpVv[3Srb36gRZN{[Xl? MYewMlEuOSEQvF2= MkXpNlTjiImqwrC= M3i1[mROW09? M3X6XolvcGmkaYTzJHBKO0tvbXXkbYF1\WRic3nncoFtcW6p MkPrNVk3OzN4OEO=
U138MG Mn;rSpVv[3Srb36gRZN{[Xl? NWDudWRJOC5zLUGg{txO M4jnTFI16oDLaNMg NHXSVIhFVVOR NH[y[2xqdmirYnn0d{BRUTONLX3l[IlifGWmIIPp[45idGmwZx?= NYnwWnpXOTl4M{O2PFM>
U118MG NXTrbpN[TnWwY4Tpc44hSXO|YYm= Mo\xNE4yNTFizszN MVSyOQKBkWkEoB?= NWX5NGF4TE2VTx?= MnvsbY5pcWKrdIOgVGk{Uy2vZXTpZZRm\CC|aXfuZYxqdmd? MWCxPVY{OzZ6Mx?=
U87MG MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfHTWM2OD1yLkG0JO69VQ>? Mly0NVk2QDR{Mke=
IGROV-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Tqd2lEPTB;MD6wOkDPxE1? MmHFNVk2QDR{Mke=
DETROIT562 M3LJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnvUXBGUUN3ME2wMlE{KM7:TR?= NUnVdmJiOTl3OESyNlc>
PC3  NVXkUmd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV24VHNGUUN3ME2wMlExKM7:TR?= MX[xPVU5PDJ{Nx?=
SKOV-3 NEPHRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PHdmlEPTB;MD6xNkDPxE1? NEnQcngyQTV6NEKyOy=>
HUVEC NXvKcHNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;ZSmlEPTB;MD6wPEDPxE1? NHOwXpcyQTV6NEKyOy=>
UCH-1  MmXxSpVv[3Srb36gRZN{[Xl? M13lVlAuPSEQvF2= MYPpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKGKxdHigRWtVKGGwZDDtWG9TKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFfnb4YyQTV{OES0NS=>
UCH-1  M3rSeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[wMlAyNTFyIN88US=> M4HMUFYh\A>? MkKwbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 NUP5fm9sOTl3Mki0OFE>
UCH-1  NV7iS5FCSXCxcITvd4l{KEG|c3H5 MmfrNE4yNTFyIN88US=> M{TnV|I1KGh? MWXEUXNQ NVzt[XJPcW6mdXPld{BieG:ydH;zbZM> Moq4NVk2Ojh2NEG=

... Click to View More Cell Line Experimental Data

In vivo試験 When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]
臨床試験
特集 The first potent, synthetic mTOR inhibitor.

プロトコル (参考用のみ)

キナーゼアッセイ: [3]

Enzyme Assays Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.

細胞アッセイ: [2]

細胞株 U87MG cells
濃度 0.5 μM
反応時間 24 hours
実験の流れ U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °

動物実験: [2]

動物モデル 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
製剤 50% DMSO
投薬量 5 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download PI-103 SDF
分子量 348.36
化学式

C19H16N4O3

CAS No. 371935-74-9
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 24 mg/mL (68.89 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-

文献中の引用 (21)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PI3K 阻害剤

  • GDC-0032

    GDC-0032は一種有効的で、次世代のβ亜型PI3K抑制剤で、PI3Kα/δ/γに作用する時のIC50値が0.29 nM/0.12 nM/0.97nMそれぞれ分かれます。GDC-0032はPI3Kα/δ/γに作用する選択性はPI3Kβに作用する選択性より10倍以上が高くなります。

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147)は一種の選択性的で、可逆なI型PI3K抑制剤で、無細胞試験でPI3Kα/δ/γに作用する時のIC50値が39 nM/36 nM/23 nMそれぞれに分かれて、PI3Kβに低い作用をしています。臨床1/2期。

  • GNE-317

    GNE-317は一種の有効な大脳浸透性のPI3K抑制剤です。

  • PI-3065

    PI-3065は一種の選択性p110δ抑制剤で、IC50値が15 nMです。PI-3065は選択性について、他のPI3K家族メンバーより70倍以上が高くなります。

  • LY294002

    LY294002は初めの合成で、PI3Kα/δ/βを抑制することが分かった小分子です。無細胞試験で、IC50値は0.5 μM/0.57 μM/0.97 μMそれぞれに分かれます。尚、溶液にの状況はワートマニン(Wortmannin)にの状況よりもっと安定になって、自食胞の形成も遮断できます。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA)は1種の選択性PI3K抑制剤で、HeLa細胞の中で、Vps34とPI3Kγに作用する時のIC50値は25μMと60μMです。3-Methyladenine (3-MA)はI型PI3Kを永遠に抑制しますが、III型PI3Kを一時に抑制して、自食体の形成も遮断します。

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101)は1種のセレクティブp110δ抑制剤です。無細胞試験で、IC50値は2.5 nMです。CAL-101 (Idelalisib, GS-1101)はp110δに表現する選択性はp110α/β/γに表現する選択性 より40-300倍が高くなって、C2β、hVPS34、DNA-PK とmTORに表現する選択性より400-4000倍が高くなります。

  • Wortmannin

    Wortmanninは一種、初めに命名されたPI3K抑制剂で、無細胞試験でIC50値が3 nMになって、PI3K家族に作用する選択性が弱くて、自食体の形成も抑制して、DNA-PK/ATMも有効に抑制して、無細胞試験で、このIC50値が16 nMと150 nMになります。

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235,Dactolisib)は一種の二重ATP競争性PI3KとmTOR抑制剤で、無細胞試験でp110α/γ/δ/β/mTOR(p70S6K)を抑制する時のIC50値は 4 nM /5 nM /7 nM /75 nM /6 nMそれぞれ分かれます。BEZ235 (NVP-BEZ235,Dactolisib)はT3TopBP1-ER 細胞の中でATRを抑制して、IC50 値が21 nMになって、Akt とPDK1に作用することが弱くなります。臨床2期。

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib)は1種のセレクティブPI3K抑制剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は52 nM/166 nM/116 nM/262 nMそれぞれに分かれます。BKM120 (NVP-BKM120, Buparlisib)はVPS34、mTORとDNAPKに作用する効果が良くなくて、PI4Kβにほとんど活性を表しません。臨床2期。

最近チェックしたアイテム

Tags: PI-103を買う | PI-103供給者 | PI-103を購入する | PI-103費用 | PI-103生産者 | オーダーPI-103 | PI-103代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ